Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
http://www.nature.com/articles/6603129.pdf
Reference32 articles.
1. Armstrong AJ, Carducci MA (2005) Chemotherapy for advanced prostate cancer: results of new clinical trials and future studies. Curr Oncol Rep 7: 220–227
2. Carles J, Domenech M, Gelabert-Mas A, Nogue M, Tabernero JM, Arcusa A, Guasch I, Miguel A, Ballesteros JJ, Fabregat X (1998) Phase II study of estramustine and vinorelbine in hormone-refractory prostate carcinoma patients. Acta Oncol 37: 187–191
3. Crawford ED, DeAntoni EP, Ross CA (1996) The role of prostate-specific antigen in the chemoprevention of prostate cancer. J Cell Biochem Suppl 25: 149–155
4. Cummings J, Ward TH, LaCasse E, Lefebvre C, St-Jean M, Durkin J, Ranson M, Dive C (2005) Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Br J Cancer 92: 532–538
5. Engels FK, Verweij J (2005) Docetaxel administration schedule: from fever to tears? A review of randomised studies. Eur J Cancer 41: 1117–1126
Cited by 75 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Key genes and molecular mechanisms related to Paclitaxel Resistance;Cancer Cell International;2024-07-13
2. Orexins and Prostate Cancer: State of the Art and Potential Experimental and Therapeutic Perspectives;Cancer Genomics - Proteomics;2023-11-30
3. Therapeutic Resistance Models and Treatment Sequencing in Advanced Prostate Cancer;Cancers;2023-11-03
4. Serum Level of Cytokeratin 18 (M65) as a Prognostic Marker of High Cardiovascular Disease Risk in Individuals with Non-Alcoholic Fatty Liver Disease;Biomolecules;2023-07-14
5. Serum gasdermin D levels are associated with the chest computed tomography findings and severity of COVID-19;Respiratory Investigation;2022-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3